Information Provided By: 
Fly News Breaks for May 23, 2017
ALXN
May 23, 2017 | 14:31 EDT
Nomura Instinet analyst Christopher Marai recommends using today's selloff in Alexion Pharmaceuticals as an opportunity to accumulate the shares. The headlines are taking the management changes out of context as Alexion confirmed the departures are part of the new CEO's plans to refocus the company, Marai tells investors in a research note. The moves are also in line with industry norms when a new CEO joins a company, he adds. The analyst keeps a Buy rating on Alexion with a $148 price target.
News For ALXN From the Last 2 Days
There are no results for your query ALXN
